Multiple Coronary Artery Disease-related targets

Multiple Coronary Artery Disease-related targets refers to a broad collection of molecular entities involved in the development and clinical manifestation of Coronary Artery Disease (CAD). This category includes key enzymes in lipid metabolism such as HMG-CoA reductase and PCSK9, which are central to the formation of atherosclerotic plaques (Khera & Kathiresan, 2017). It also encompasses receptors and enzymes that regulate hemodynamic stability and thrombosis, such as the beta-1 adrenergic receptor and the P2Y12 platelet receptor (Valgimigli et al., 2018). Because CAD is a multifactorial disease driven by genetics, lifestyle, and metabolic factors, therapeutic strategies often involve targeting several of these pathways simultaneously to reduce the risk of myocardial infarction and stroke (Mach et al., 2020). This term is considered 'incorrect' as a single therapeutic target because it represents a therapeutic area or a group of distinct proteins rather than a specific, individual molecule. Biotech analysts should view this entry as a summary of the diverse pharmacological landscape required to manage cardiovascular risk.

Other names

Multiple CAD-related targetsCoronary artery disease targetsIschemic heart disease targetsAtherosclerotic cardiovascular disease targets

Inhibition of HMG-CoA reductase to lower cholesterol; inhibition of PCSK9 to increase LDL receptor density; antagonism of P2Y12 receptors to prevent platelet aggregation; inhibition of ACE to reduce blood pressure; and blockade of beta-1 adrenergic receptors to reduce cardiac workload.